<img src="https://ml.globenewswire.com/Resource/Download/12db9039-d4bf-41a0-8b4a-324398e392b4?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Neuronetics_logo-RGB purple.png" alt="Neuronetics"/>MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that management will participate at the B. Riley Securities' Mind, Muscle &amp; Vision Summit, an invitation-only institutional investor event being held in-person at the InterContinental Boston. Neuronetics will participate in a panel discussion titled "Commercializing the Next Wave of Novel Neuropsychiatric Drugs," alongside Compass Pathways, scheduled for Thursday, July 16, 2026. Management will also be available for one-on-one meetings with institutional investors throughout the day. This is an in-person, invitation-only event, and there will be no live webcast of the panel discussion. About Neuronetics Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit <a href="https://www.globenewswire.com/Tracker?data=5yyTadBWYufroaECHRtZEGX9AIzZq1QG7YnjUtBbAR5LaYYXKXGriZK25WZxC_vA6jHVr_QvCHFylAFgKsB8HQ==" rel="nofollow" target="_blank" title="">NeuroStar.com</a>. Investor Contact: Mike Vallie or Mark Klausner ICR Healthcare 443-213-0499 <a href="https://www.globenewswire.com/Tracker?data=kqsyki6cssuPVvUP-MRuB0fwwyb8tMaoTW8AxJxhakDFkN9ozmNKuTI2cL9vw2goSVqnUmUWiBhVjylN2kL4D5UCnewiGUcYjcCXUfb-rt7Rc-xq0xg0ZVsUczXlQe0_ll0KXk6ASsUFI0xtZ2_SMc7-3zauecvfacDmJvEdAa_WW6_jxqhpF5793w3UHq3awORdTm9IB4L__-KrnwmB47uQIu4hhzJ-IFYFj1Gzpc2LwkTl5s3COqYH80IWWZ9yHblusQS4an3Aqzzg-E1vqg==" rel="nofollow" target="_blank" title="">ir@neuronetics.com</a> Media Contact: EvolveMKD 646-517-4220 <a href="https://www.globenewswire.com/Tracker?data=5yyTadBWYufroaECHRtZEJFDVEip2ikDmI8qHVUd_ZREr5sQslwQsxSjd2cVf8F3dBxH34uXPkEsQSm6dqtra7c6fDI-5SDb2NabK9wAqVo=" rel="nofollow" target="_blank" title="">NeuroStar@evolvemkd.com</a> References 1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit <a href="https://www.globenewswire.com/Tracker?data=HqhDK8s6q2fwnAuzhZLkiYzpBD4HZV768DH4LTvryGTMDCqw2kd0NGs49KsQsW5l74KOn92VFO4S1FIbNzxFsC0RwQgGfRlQW3qolD2-qkk=" rel="nofollow" target="_blank" title="">spravatohcp.com</a>. <img alt="" src='https://ml.globenewswire.com/media/MDQ2OWU5NzktNDZlMC00YjQ3LTk0MzQtZjIyYzFlZGMyMTlkLTExMjIwMTEtMjAyNi0wNy0wNi1lbg==/tiny/Neuronetics.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn